Worsening heart failure (WHF) is a severe and dynamic condition characterized by
significant clinical and hemodynamic deterioration. It is characterized by worsening HF …

Regardless of the currently proposed best medical treatment for heart failure patients, the
morbidity and mortality rates remain high. This is due to several reasons, including the …

Synergistic effects of MRA and SGLT2i in HF: Key beneficial effects (+) of mineralocorticoid
receptor antagonists (MRA) and sodium–glucose co-transporter inhibitors (SGLT2i) on …

Vericiguat, the newest soluble guanylate cyclase (sGC) drug, is potentially beneficial in
treating heart failure (HF). However, most studies have only confirmed the significant impact …

Patients with an established diagnosis of heart failure (HF) with reduced ejection fraction
(HFrEF) are prone to experience episodes of worsening symptoms and signs despite …

Invasive hemodynamic studies have shown improved left ventricular (LV) performances
when cardiac resynchronization therapy/defibrillator is delivered through multipoint pacing …

Heart failure is the most costly cardiovascular disorder. New treatments are urgently needed.
This study aims to evaluate the safety, pharmacokinetics, and pharmacodynamic profile of …

Background: Vericiguat was developed to treat patients with heart failure (HF). Currently,
limited data are available to characterize vericiguat-treated patients in real-world clinical …

Heart failure with reduced ejection fraction (HFrEF) represents an emerging epidemic,
particularly affecting frail, older, and multimorbid patients. Current therapy for the …

SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction.
ARNI, angiotensin receptor–neprilysin inhibitor; CV, cardiovascular; GRMT, guideline …